Abstract
AbstractMatrix metalloprotease inhibitor (MMPi) drug discovery initially focused on the therapeutic use of these compounds as antineoplastic and antiarthritis agents to reduce metastases and joint matrix degradation, respectively. However, increased MMP expression has been shown to occur after myocardial ischemia (MI) and during progressive heart failure (HF). Inhibition of MMP activity has been shown to limit left ventricular aneurysm, slow atherosclerotic plaque progression, and reduce left ventricular dilation after MI in mice as well as preserving left ventricular geometry and function in several animal HF models. A growing literature indicates that MMPi treatment may represent a novel therapeutic strategy in the treatment for a variety of cardiovascular diseases, especially prevention of heart failure. The objective of this article is to define the role of MMPs in HF, identify which MMPs are upregulated, and outline potential limitations of MMPi therapy in this disease. Drug Dev. Res. 55:29–44, 2002. © 2002 Wiley‐Liss, Inc.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
